Overview

• Pfizer confirmed an agreement to reduce prices on select medicines, including lower prices for some drugs supplied to Medicaid, according to White House officials and the company.
• A 100% tariff on imported branded or patented pharmaceuticals takes effect Oct. 1 for manufacturers not building U.S. plants, with European Union products subject to a 15% levy and generics excluded.
• The administration is launching a TrumpRx direct-to-consumer website for discounted purchases, though which drugs will be offered and who can use the site have not been detailed.
• HHS and CMS introduced a GLOBE pricing model as the Sept. 29 deadline passed for drugmakers to commit to Most Favored Nation terms, while several companies and PhRMA expanded direct-purchase programs.
• Experts warn of legal and operational hurdles, noting tariff codes do not separate brands from generics and raising concerns about supply disruptions as trade and pricing rules are enforced.